Sabon Nazari Yana Nufin Matsakaici zuwa Tsananin Osteoarthritis na Knee

Ageless Biotech, Inc. Sheridan, WY wani kamfani na biotech da aka ƙirƙira don kawo magungunan tushen ƙwayoyin cuta zuwa kasuwa, ya sami Cibiyar Nazarin Abinci da Magunguna ta Amurka (FDA) don maganin Osteoarthritis na Knee.              

Gidauniyar Arthritis ta bayyana Osteoarthritis a matsayin "cuta ta yau da kullun… ba tare da magani ba." Fiye da shekaru goma da suka wuce a cikin 2009 ABC News da aka buga, kula da lafiyar marasa lafiya na osteoarthritis a Amurka yana kashe dala biliyan 185.5 a shekara.

A cikin ɗan gajeren shekaru 4 kawai, daga Gidauniyar Arthritis Foundation ta 2009 ta bayar da rahoton cewa farashin OA a Amurka ya ninka kamar yadda aka buga a cikin 2013 ta rahoton CDC cewa farashin Osteoarthritis na shekara “sun kasance $303.5 biliyan ko 1% na 2013 US Gross Domestic Product (GDP) .”  

Shugaban Kamfanin Ageless Biotech, Inc, Vince Liguori ya yi nuni da cewa, “Samun Mataki na II OA na Gwajin Jiki na Knee yana ba mu damar fara gwaji da sauri tare da shirye-shiryen farawa a ƙarshen Maris 2022. Wannan FDA ta karɓi IND ta ba da damar shekaru marasa shekaru. Biotech don kawo samfurin Osteoarthritis Stem Cell ga duka Likitoci da Marasa lafiya cikin hanzari."

The Ageless Biotech IND yana amfani da ƙananan ƙwayoyin adipose da aka samo asali ba tare da enzymes ko wasu sinadarai ba ta hanyar tsarin mallakar mallakar sanannen hanyar da ake kira Stromal Vascular Fraction (SVF) wanda ke haifar da matrix na sel ɗan adam. Ageless Biotech yana shirin tabbatar da kaddarorin sabuntawa na samfuran Ageless Biotech SVF kafin ƙarshen wannan Nazarin Nazari na FDA da aka yarda da shi yayin da yake nuna aminci da ƙarancin ƙarancin lokaci ga majiyyaci. Ageless Biotech ya yi imanin cewa miliyoyin tiyatar gwiwa na shekara-shekara za a maye gurbinsu da allurar gwiwa guda daya mai sauki. Duk da yake mun yi imanin cewa a ƙarshe za a ba da lasisin wannan fasaha ga likitocin don rarraba jama'a, muna zazzagewa "a kan shiryayye" zaɓuɓɓukan masu yarda da nau'in HLA don yaba irin waɗannan hanyoyin kwantar da hankali a nan gaba "ba mai nisa ba".

Daraktan Tallace-tallace na BioXstem na Kasa, kuma Memba na Hukumar Kula da Biotech Ageless Jon Youngs ya ce, “Mu a BioXstem muna matukar farin ciki da kasancewa mai saka hannun jari na Ageless Biotech wanda a yanzu ba kawai magana muke yi ba. A zahiri muna iya cewa muna taka rawa sosai a cikin FDA IND da kuma wani bangare na jagoranci na ci gaban magani. ”